Roth Capital Weighs in on Orthofix Medical Inc.’s Q1 2025 Earnings (NASDAQ:OFIX)

Orthofix Medical Inc. (NASDAQ:OFIX) – Investment analysts at Roth Capital issued their Q1 2025 earnings per share estimates for shares of Orthofix Medical in a note issued to investors on Monday, May 6th. Roth Capital analyst J. Wittes anticipates that the medical device company will post earnings of ($0.25) per share for the quarter. The consensus estimate for Orthofix Medical’s current full-year earnings is ($1.51) per share. Roth Capital also issued estimates for Orthofix Medical’s Q2 2025 earnings at ($0.04) EPS, Q3 2025 earnings at ($0.04) EPS and Q4 2025 earnings at $0.15 EPS.

Orthofix Medical (NASDAQ:OFIX) last released its earnings results on Tuesday, March 5th. The medical device company reported ($0.59) EPS for the quarter, topping analysts’ consensus estimates of ($0.60) by $0.01. Orthofix Medical had a negative return on equity of 10.63% and a negative net margin of 20.28%. The firm had revenue of $200.42 million during the quarter.

A number of other research firms also recently issued reports on OFIX. StockNews.com downgraded shares of Orthofix Medical from a “hold” rating to a “sell” rating in a research report on Wednesday, March 6th. Roth Mkm upped their target price on Orthofix Medical from $12.00 to $15.00 and gave the stock a “neutral” rating in a research note on Thursday, March 7th. Finally, JMP Securities reiterated a “market perform” rating on shares of Orthofix Medical in a research report on Monday, April 22nd. One equities research analyst has rated the stock with a sell rating and four have issued a hold rating to the company’s stock. According to MarketBeat, the company has an average rating of “Hold” and a consensus price target of $15.50.

Orthofix Medical Stock Performance

Shares of NASDAQ OFIX opened at $13.89 on Tuesday. The stock has a market cap of $519.62 million, a price-to-earnings ratio of -3.36 and a beta of 1.06. Orthofix Medical has a 12 month low of $9.57 and a 12 month high of $21.60. The company has a 50 day simple moving average of $13.63 and a two-hundred day simple moving average of $13.02. The company has a current ratio of 2.54, a quick ratio of 1.20 and a debt-to-equity ratio of 0.19.

Institutional Inflows and Outflows

Large investors have recently modified their holdings of the company. Gladius Capital Management LP grew its position in shares of Orthofix Medical by 55.2% during the 4th quarter. Gladius Capital Management LP now owns 2,841 shares of the medical device company’s stock valued at $38,000 after acquiring an additional 1,010 shares during the period. Zurcher Kantonalbank Zurich Cantonalbank increased its position in shares of Orthofix Medical by 30.4% in the fourth quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 7,516 shares of the medical device company’s stock valued at $101,000 after buying an additional 1,752 shares in the last quarter. State Board of Administration of Florida Retirement System acquired a new position in shares of Orthofix Medical during the 3rd quarter worth approximately $130,000. Teza Capital Management LLC purchased a new position in shares of Orthofix Medical during the 3rd quarter valued at approximately $133,000. Finally, Arizona State Retirement System acquired a new stake in Orthofix Medical in the 4th quarter valued at $138,000. Institutional investors and hedge funds own 89.76% of the company’s stock.

Orthofix Medical Company Profile

Orthofix Medical Inc operates as a spine and orthopedics company in the United States, Italy, Germany, the United Kingdom, France, Brazil, and internationally. It operates through two segments, Global Spine and Global Orthopedics. The Global Spine segment manufactures and distributes bone growth stimulator devices for enhance of bone fusion, including adjunctive and noninvasive treatment of cervical and lumbar spine, as well as a therapeutic treatment for non-spine; designs, develops, and markets a portfolio of motion preservation and fixation implant products, which are used in surgical procedures of the spine; and offers biological products, such as fiber-based and particulate demineralized bone matrices, cellular bone allografts, collagen ceramic matrices, and synthetic bone void fillers, and tissue forms, which allow physicians to treat various spinal and orthopedic conditions.